Search research articles
Contact Us
Filters
Showing results (11-20 of 149) with videos related to
Page
of 15
Sort By:
Oral Oncology
|
July 9, 2013
Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes
Mark A Lerman, Wanling Xie, Nathaniel S Treister, et al.
Prostate Cancer and Prostatic Diseases
|
January 8, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer
Praful Ravi, Wanling Xie, Silke Gillessen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia
Xavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
Clinical Genitourinary Cancer
|
March 27, 2026
Monitoring of Disease in Patients Receiving <sup>177</sup>LU-PSMA-617 Therapy in Routine Practice
Narmeen S Rashid, Caiwei Zhong, Wanling Xie, et al.
The Oncologist
|
July 18, 2023
TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
Talal El Zarif, Marc Machaalani, Rashad Nawfal, et al.
The Prostate
|
June 22, 2016
A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer
Wanling Xie, Sarah Drouin, Mari Nakabayashi, et al.
Cancer
|
May 23, 2026
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis
Johnathan Zeng, Ming-Hui Chen, Jing Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2006
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer
Mary-Ellen Taplin, Wanling Xie, Glenn J Bubley, et al.
JAMA Oncology
|
October 20, 2017
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
Jason W D Hearn, Wanling Xie, Mari Nakabayashi, et al.
The Prostate
|
August 14, 2012
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer
Han Christine Ngoc Nguyen, Wanling Xie, Ming Yang, et al.
Page
of 15
Search research articles
Search
Showing results (11-20 of 149) with videos related to
Sort By:
Page
of 15
Oral Oncology
|
July 9, 2013
Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes
Mark A Lerman, Wanling Xie, Nathaniel S Treister, et al.
Prostate Cancer and Prostatic Diseases
|
January 8, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer
Praful Ravi, Wanling Xie, Silke Gillessen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia
Xavier Leleu, Wanling Xie, Meghan Bagshaw, et al.
Clinical Genitourinary Cancer
|
March 27, 2026
Monitoring of Disease in Patients Receiving <sup>177</sup>LU-PSMA-617 Therapy in Routine Practice
Narmeen S Rashid, Caiwei Zhong, Wanling Xie, et al.
The Oncologist
|
July 18, 2023
TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
Talal El Zarif, Marc Machaalani, Rashad Nawfal, et al.
The Prostate
|
June 22, 2016
A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer
Wanling Xie, Sarah Drouin, Mari Nakabayashi, et al.
Cancer
|
May 23, 2026
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis
Johnathan Zeng, Ming-Hui Chen, Jing Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2006
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer
Mary-Ellen Taplin, Wanling Xie, Glenn J Bubley, et al.
JAMA Oncology
|
October 20, 2017
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
Jason W D Hearn, Wanling Xie, Mari Nakabayashi, et al.
The Prostate
|
August 14, 2012
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer
Han Christine Ngoc Nguyen, Wanling Xie, Ming Yang, et al.
Page
of 15